Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 Expo Consumer Cannabis Convention In NJ To Draw over 15,000 Enthusiasts

The third annual 420 Expo Cannabis Convention will be held Sept 13-15, 2024 at the New Jersey Convention & Exposition Center. The event is expected to bring over 15,000 cannabis enthusiasts together for three days of networking with cannabis industry traders from all over the country. In addition, the convention will feature seminars, panel discussions, food, music, after parties, and exciting giveaways.

The event will also showcase a first-of-its-kind contest for licensed cultivators across the Garden State to compete for the 420 Expo Cannabis Cup until Sunday, July 28. In addition, B-Real, lead rapper of the multi-platinum hip-hop group Cypress Hill, will be gracing the event as guest of honor.

420 Expo is a well-organized event, curated by a team of enthusiastic professionals with significant cannabis industry experience, encouraging the local cannabis community by bringing together investors, young and veteran cannabis vendors, creatives, and enthusiasts, on a dynamic common forum.

New Jersey became the fourteenth state to legalize marijuana completely, on February 22nd, 2021. Atlantic City has a flourishing cannabis market waiting to get tapped by industry experts. The 420 Expo will bring tremendous business and collaboration opportunities to the New Jersey cannabis community.

The 420 Expo offers an interactive forum for new cultivators to exhibit their products before cannabis traders, connoisseurs, and enthusiasts. More than 100 vendors covering dispensaries, CBD traders, food, clothing, art and more will be setting up display booths.

Experts will shed light on topics such as selecting the right cannabis strains, legal expungement, cannabis to help addiction and recovery, investments, and more, at the roundtables and discussion panels. The expo seminar will spotlight topics such as medical marijuana, networking in cannabis, social equity, legal rights, cooking with cannabis, and more.

Tickets for 420 Expo are now available for general admission, VIP access, and bucket list smoke sessions.

To learn more please visit https://cnw.fm/Cu5yY

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Strengthening Cannabis Foothold as CSA Status Set to Change

  • An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center
  • The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act
  • MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts

With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is positioning itself for marked growth and success in the coming months. The company’s goal is to be the world’s premier resource for pharmaceutical cannabis products.

“As more states pass laws legalizing marijuana for recreational use, Americans continue to favor legalization of both medical and recreational use of the drug,” revealed a recent Pew Research Center survey (https://cnw.fm/fCQAD). “An overwhelming share of U.S. adults (88%) say marijuana should be legal for medical or recreational use.

“Nearly six in ten Americans (57%) say that marijuana should be legal for medical and recreational purposes, while roughly a third (32%) say that marijuana should be legal for medical use only,” the report continued. “Just 11% of Americans say that the drug should not be legal at all.”

After many years, the federal government is seemingly catching up to public opinion. In May the Justice Department announced that the attorney general had submitted official notice to begin the process of considering moving marijuana from a Schedule 1 to Schedule 3 drug under the CSA (https://cnw.fm/xHGvC).

“Marijuana has been classified as a Schedule 1 drug since Congress enacted the CSA in 1970,” the announcement noted. “On Oct. 6, 2022, President Biden asked the attorney general and the secretary of Health and Human Services (‘HHS’) to launch a scientific review of how marijuana is scheduled under federal law. After receiving HHS’s recommendations last August, the attorney general sought the legal advice of the Justice Department’s Office of Legal Counsel (‘OLC’) on questions relevant to this rulemaking. In light of HHS’s medical and scientific determinations, and OLC’s legal advice, the attorney general exercised his authority under the law to initiate the rulemaking process to transfer marijuana to Schedule 3.”

The process to make the change includes several steps, including a public comment period and final judicial review. “Still, the reclassification of cannabis would mark a new era in America’s often contradictory relationship with a substance already legalized in one form or another in more than half the states,” stated an article in The Week (https://cnw.fm/3pLq1).

The Week noted that perhaps the most significant change reclassification would bring would be increasing governmental ability to conduct further research into the health benefits of cannabis. The article stated that “reclassification also means the government acknowledges cannabis, like all other Schedule 3 substances, has an ‘accepted medical use and may lawfully be dispensed by prescription,’ the Congressional Research Service said. However, any such prescriptions must be approved by the Food and Drug Administration.

“Beyond expanding and easing access to federal research opportunities, reclassifying cannabis will have a major impact on the booming — but still legally murky — marijuana industry as a whole,” the article observed.

With these looming changes as a backdrop, MedCana’s commitment to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world is perfectly timed. Committed to absolute integrity, sustainability and social responsibility, MedCana is a holding company focused on developing companies in the agricultural-technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Feds Outline Research Priorities on Cannabinoids, Medical Marijuana

Health officials at the federal level have outlined research priorities on cannabinoids and cannabis in a new report by the National Center for Complementary and Integrative Health (NCCIH). The report highlights efforts by the NCCIH and other National Institutes of Health (NIH) entities to bridge the gap between the medicinal use of cannabis and the research informing its efficacy and safety.

Key areas of research include the effects of cannabis on social anxiety, pain and sleep; the use of terpenes therapeutically; the use of computers to identify bioactive minor cannabinoids in hemp; and the chemical synthesis of uncommon cannabinoids.

Funding opportunities were introduced by NCCIH in 2019, and $3 million in grants was awarded to researchers to investigate the mechanisms of action and possible pain-relieving properties of phytochemicals found in cannabis. This initiative included minor cannabinoids, excluding delta 9 THC, and terpenes.

Over the years, research has expanded to cover several key areas, including investigating the impact of CBD on arthritis-related chronic pain; determining the effects of uncommon cannabinoids on microglia; investigating the role of terpenoid and CBD interactions in the control of pain states by the amygdala; and testing terpenes and cannabinoids separately and in combination for morphine-induced pain alleviation in mouse models, among others.

In addition to advancing scientific studies, NIH is supporting the creation of a Resource Center for Cannabinoid and Cannabis Research. The center aims to assist researchers in overcoming barriers and challenges, both scientific and legal, which stand in the way of studying marijuana and its components.

Funding for the center will come from a $1 million allocation from NCCIH in the fiscal year 2025, with cofunding from NCI, NIA and NIDA totaling $100,000 each. Additionally, NCI recently awarded researchers $3.2 million to study the effects of marijuana use during immunotherapy for cancer treatment.

The agency’s website compiles information about the NIH cannabinoid and cannabis research program, including pertinent staff contacts, funding opportunities, priorities and access to research grant applications that are currently being financed.

NCCIH representatives, along with representatives from other federal health entities, convened recently to deliberate on the present status of cannabis research and policy implications for researchers examining cannabis while it remains illegal. The discussion focused on terpenes and cannabinoids’ potential to alleviate pain.

Craig Hopp, deputy director of NCCIH’s extramural research unit and coauthor of the new paper, discussed the U.S. Department of Justice’s recent proposal to reclassify cannabis under the Controlled Substance Act from Schedule 1 to 3, describing it as the elephant in the room for researchers.

While cannabis advocates and researchers have emphasized the potential for a Schedule 3 reclassification to reduce research obstacles related to Schedule 1 substances, Hopp stated that nothing has changed yet in the early phases of the regulation process. He further noted that any modifications won’t happen for at least a year and that it’s still unclear if a Schedule 3 status will eventually enable academics to obtain marijuana for research purposes from state-licensed dispensaries.

Notwithstanding the difficulties in researching restricted substances, the burgeoning legalization movement has coincided with a rise in research. Over the past 10 years, academics have published more than 32,000 studies on marijuana, with recent years setting records for study, according to NORML.

As more marijuana studies are published, they could help companies in the industry such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) to keep tweaking their offerings in order to better address the needs of their customers, especially those using medical marijuana products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH), Lavish Entertainment Report on Progress of One-of-a-Kind Entertainment Destination

  • New project “set to transform luxury entertainment and hospitality,” according to company officials
  • Critical development has included work on infrastructure and improvements
  • Officials also focused on obtaining required permits, assembling key leadership and identifying ideal vendors

A luxury destination featuring world-class entertainment, opulent accommodations and immersive experiences is rising in the Mojave Desert. The unique property, called Destino Ranch, is a bold, visionary project envisioned by Golden Triangle Ventures (OTC: GTVH) and its wholly owned subsidiary, Lavish Entertainment.

Golden Triangle and Lavish Entertainment recently provided an update (https://cnw.fm/Rfq7n) on the one-of-a-kind project, which is “set to transform luxury entertainment and hospitality.” According to the report, “Upon taking possession of the nearly 70-acre ranch and its overall infrastructure, which included 643 trees, only 35% of the irrigation system was properly functional while most watering was done using a water truck. Today, 98% of the irrigation system is now operational following a massive overhaul.

“Key improvements include replacing and updating 95% of all control valves, re-energizing all existing waterlines and making numerous major system enhancements,” the report continued. “The extensive cleanup efforts have also included the repair of perimeter fencing, reinstallation of gates and opening of roadways around the project.”

The report noted that improvements in the water supply system, such as updating lines and control valves to the storage system and revamping the well system, have been made. In addition, substantial effort has gone into caring for the ranch’s trees, which contributes significantly to the way the property looks.

“Tree care has been a primary focus, involving pruning and trimming for health benefits and ongoing fruit production,” the company reports. “All dead trees have been removed, and new planting is planned to further enhance the project by adding additional fruit trees and various ornamental shade trees. Plans include adding numerous colorful trees and plants to create a park-like atmosphere, improving the environment and enhancing the overall aesthetic appeal of Destino Ranch.”

Along with efforts made on the actual property, company officials are focused on logistics, working closely with city planners and council members to obtain required permits and approvals for the project. “This comprehensive effort encompasses the creation of detailed development and engineering plans, alongside strategizing the acquisition of additional property essential for the project’s completion,” the report noted. “The company is actively engaged in future concept planning to ensure long-term success.”

Finally, a key part of Destino Ranch’s success will depend on management. Lavish Entertainment is dedicated to assembling an experienced, professional board of team members and directors along with identifying key vendors and determining specific site placements. Plans call for the development of a detailed site map to guide the progress of Destino Ranch.

A multifaceted consulting company, Golden Triangle Ventures operates as a parent business pursuing ventures in the health, entertainment and technology sectors. The company is looking to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

  • Lexaria, a global innovator in drug delivery platforms, recently hired a contract research organization (“CRO”) for its upcoming chronic human study, GLP-1-H24-4
  • This study will seek to evaluate various glucagon-like peptide-1 (“GLP-1”) formulations, processed with the company’s patented DehydraTECH(TM) technology
  • The study will feature five arms, with each conducted using several investigational sites in Australia

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study will seek to evaluate various glucagon-like peptide 1 (“GLP-1”) formulations processed with the company’s patented DehydraTECH(TM) technology, which has demonstrated enhanced bioavailability in multiple studies. It will also explore other treatments with efficacy objectives, including, but not limited to, blood sugar reduction and weight loss (https://cnw.fm/dCDXV).

“This study will be the most comprehensive and impactful GLP-1 investigation that Lexaria has ever undertaken,” noted John Docherty, Lexaria’s President.

“The greatly expanded scope compared to our previous studies will allow us to investigate DehydraTECH-GLP-1 safety and efficacy over an extended treatment duration to significantly broaden our knowledge of DehydraTECH’s ability to potentially improve the effectiveness and tolerability of this world-leading class of drugs,” he added.

This study will have five active treatment arms, each with 16 diabetic patients. The first arm will use Rybelsus(R) as a positive control; the second will utilize DehydraTECH-CBD, the third will feature DehydraTECH-semaglutide while the fourth will see a combination of DehydraTECH-CBD and DehydraTECH-semaglutide. The last arm will feature DehydraTECH-tirzepatide. Each patient will be dosed orally daily, subject to change once the final protocol is complete.

Each of these arms of the study will be conducted using several investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. Once completed, the study is expected to be equally regarded as a Phase 1b registrational study by the U.S. Food and Drug Administration (“FDA”).

For Lexaria, this marks a significant milestone in its quest to offer a viable treatment option for diabetes. In 2022, its DIAB-A22-1 multi-week rodent study utilizing DehydraTECH-CBD demonstrated weight loss of 7% and reduced blood glucose levels of 19.9%+/-7%. In January 2024, the company discovered that DehydraTECH processing of Rybelsus(R)-branded semaglutide, after a single dose, improved blood sugar control and reached higher levels of semaglutide measured in blood than did Rybelsus(R) itself. The company looks to establish whether this improved pharmacokinetic performance could lead to improved weight loss and/or blood-sugar control compared to Rybelsus(R) alone after multi-week dosing.

Study preparations with the CRO are already in the works pursuant to an initial start-up agreement under which several activities will occur, such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning. Lexaria’s management is optimistic that the results from this undertaking will be positive, further exemplifying the potential of its DehydraTECH technology and showcasing its overall viability in the potential treatment of diabetes and weight loss.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Maryland Celebrates a Year of Adult-Use Cannabis, Pardons and Massive Growth Realized

Maryland saw a windfall of more than $14 million from cannabis sales taxes in just the first quarter of this year. As the state celebrates the first anniversary of legal recreational cannabis, sales continue to climb.

Connor Whelton, ReLeaf CEO and cofounder, says business is thriving in this environment. He and his team have introduced creative ways to serve their customers. From home-delivery services to a walk-up window and an inviting in-store menu, the Maryland-based company made accessibility a priority. Whelton says he notices a shift in his clientele as the negative perceptions of marijuana diminish.

With recreational cannabis now legal in 24 states, the U.S. Drug Enforcement Administration is working on reclassifying the substance to a less hazardous category under the Controlled Substance Act (CSA).

According to a Carnegie Mellon University survey, the number of daily cannabis users has surpassed that of regular alcohol drinkers for the first time, with younger persons being the main drivers of this development. Further, a 2022 New Frontier Data survey found that 69% of adults between the ages of 18 and 24 would rather use cannabis than alcohol.

Maryland legalized adult-use marijuana in July 2023. The excitement was palpable, with many eagerly lining up to make their purchases. Since then, recreational sales have surpassed medical sales.

Recreational sales have generated $462 million in sales so far this year, with sales of $63 million in April alone, compared to $30 million in medical sales. The comptroller’s office reported that from January to March, the state collected $14.6 million in sales taxes. With $6.7 million, the D.C. region made the largest contribution, followed by the Baltimore region with $3.7 million. Additionally, more than $4 million will be reinvested in lower-class communities affected by the drug wars.

Ben Burstein of Leaf Link, a wholesale marketplace, praised Maryland’s market launch as one of the most successful in the decade-long history of legal marijuana sales. He noted that the state’s sales have more than doubled since the introduction of the recreational market.

However, marijuana retail prices in the state remain relatively high, with the median price per gram being $9.64. “Maryland had the highest pricing per unit in the country last summer. Although prices have begun to decline, they are still expensive in comparison to other states,” noted Burstein.

The state recently gained national attention when Governor Wes Moore pardoned more than 175,000 individuals convicted of minor cannabis-possession charges. The state has also launched a program to help those formerly convicted secure jobs in the marijuana industry.

Equity has been a focal point in Maryland’s licensing process. The state made history by becoming the first to offer a licensing round limited to eligible social-equity candidates for all license types.

The booming market for adult-use marijuana in Maryland is likely to spawn many success stories by licensed companies in the state following the trajectory of more successful entities elsewhere that are operating in other legal markets within the country, such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ).

NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Dedicated to Creating Unparalleled Tech, Labs, Facilities and Teams in Cannabis Space

  • MedCana offers a long list of proprietary essential services to its clients
  • The company’s team of pharmaceutical scientists includes some of the world’s most respected chemists
  • From initial grow to final product, MedCana helps partners produce pharmaceutical CBD and other extracts that have no equal

As the cannabis industry prepares to enter a new era with a pending schedule change in the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is committed to being a worldwide force for high-quality cannabis products. To achieve this lofty goal, the company is focused on building the technology, laboratories, growing facilities, and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world (https://cnw.fm/858iB).

Leading the way forward in the cannabis space, the company offers a long list of essential resources and services for its clients. That list includes proprietary blockchain technology to track every product from seed to the growing facility to the final product; a team of expert scientists, engineers and chemists from the United States and Colombia; state-of-the-art laboratory equipment; partners with growing facilities in Colombia; and an impressive international management team from the U.S. and Colombia.

MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. This extraordinary group is committed to ensuring that MedCana customers and partners can create premium pharmaceutical-grade cannabis extracts that satisfy the growing worldwide demand while also meeting the highest industry standards.

Unlike any other software in the market, the company’s proprietary software ensures traceability and quality from seed to products. In addition, one of MedCana’s partners will be a globally certified lab that will provide certification for distribution through the Pharmaceutical Inspection Co-operation Scheme (PIC/S). PIC/S presently comprises 54 participating authorities worldwide, including Europe, Africa, America, Asia and Australia.

As MedCana works to achieve its objective of becoming a worldwide cannabis-market force, the company’s initial emphasis is on partnering with and developing companies in Latin America with a focus in Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. “MedCana’s advantage is our global view and reach,” the company states. “From initial grow to final product, we’ll be helping partners produce pharmaceutical CBD and other extracts that will have no equal.”

Software Effective Solutions is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company rounds out MedCana’s portfolio of holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida’s Marijuana Legalization Ballot Measure Could Face Heavily Funded Opposition

The recreational cannabis legalization campaign in Florida is up against a significant new challenge: heavily funded opposition. Florida Governor Ron DeSantis (R) recently created the Florida Freedom Fund, allowing him to receive unlimited donations aimed at achieving the fund’s specific goals.

A primary objective of the fund is to thwart Amendment 3, which proposes to legalize recreational marijuana and permit sales at already-existing medical cannabis dispensaries. In the unlikely event that DeSantis is successful in garnering national attention and support for this cause, the legalization of recreational marijuana may not be supported by a larger financial advantage throughout its campaign.

Smart and Safe Florida spokesperson Morgan Hill noted that a recent survey indicated 66% of probable voters support the ballot measure. In Florida, a constitutional amendment must receive the support of at least 60% of voters to pass, a rather high percentage.

In contrast, Ohio’s recreational cannabis was approved by more than 57% of voters last year. The opposition there managed to collect contributions totaling only $927,900, while the pro-legalization campaign raised more than $6.7 million.

Florida represents a crucial market for marijuana businesses, being the largest domestic medical cannabis market, with strict state laws limiting the number of participants. The stakes in Florida are high, especially because it’s a presidential battleground state, and the legalization measure will appear on the same ballot as President Joseph Biden and Florida resident and presumed GOP contender Donald Trump.

Biden is anticipated to focus some of his campaign on marijuana reform to win over young people following his executive order from 2022, which prompted the U.S. DOJ to propose cannabis rescheduling. Trump has not yet taken a stance on Florida’s recreational cannabis legalization, but DeSantis, a former presidential contender, has expressed strong opposition.

The DeSantis fund is also targeting a measure that seeks to overturn a law he signed earlier prohibiting abortion procedures beyond the six-week pregnancy mark. The governor has labeled both measures as quite excessive.

Political analysts speculate that the confluence of these concerns may boost female and younger voter turnout, which might help Democratic candidates such as Biden.

There’s been significant fundraising done to support the two measures. The Tampa Bay Times reported that the abortion protection proposal has received $12 million in contributions since April. In the meantime, supporters of cannabis legalization have invested more than $40 million in Florida. The leading contributor remains Trulieve, which added another $5 million in April.

Marijuana companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) will be hoping that, at the end of the day, the true will of the people of Florida carries the day on polling day regardless of which way the ballot swings.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Kentucky to Start Receiving Applications from Medical Marijuana Companies

Businesses in Kentucky looking to grow, process or sell medical cannabis can start submitting applications for licenses on Monday, July 1, 2024. Governor Andy Beshear announced this as part of an expedited effort to have products on the market by early 2025.

Healthcare providers, including advanced-practice registered nurses and doctors, can also start applying to certify qualified patients for purchasing medical cannabis. The process will be overseen by the state’s Board of Medical Licensure and Board of Nursing.

The state’s medical marijuana program is officially scheduled to kick off on Jan. 1, 2025. The legislation, passed in 2023 with bipartisan support in the GOP-dominated state assembly, legalizes medical marijuana for individuals with a range of debilitating conditions. Beshear signed the law promptly, and his administration has been diligently working on the program’s regulations ever since.

To accelerate the process, Beshear signed additional measures this spring, advancing the timeline for marijuana business registration by six months.

To help applicants, the state has made several YouTube seminars, a handbook for business license applications and other materials available. Companies have until August 30 to submit their licensing applications. According to Beshear, the objective is to have medical marijuana accessible by January, coinciding with the legalization of these goods.

Medical marijuana cards will be available for application starting the first of  the year to patients with qualifying diseases such as multiple sclerosis, cancer, chronic epilepsy and post-traumatic stress disorder (PTSD) as well as chronic pain and nausea.

Eric Friedlander, the secretary of Kentucky’s Health and Family Services, underlined the commitment of the state to providing affordable and safe access to medical marijuana for people with qualifying conditions.

Beshear noted in April that the first round of company licenses would be distributed by the state through a lottery. The program’s goal, according to Sam Flynn, director of the state’s Office of Medical Marijuana, is to guarantee that marijuana licensing is equitable, open and focused on the needs of customers.

Initially, the state will issue 48 store licenses, distributed among 11 regions, with each area receiving at least four licenses. Most counties will be limited to one dispensary license each, except for the counties housing Lexington and Louisville, which will be allocated two licenses each.

The first wave of the license lottery is scheduled for October 2024. A restricted number of licenses for cannabis cultivation and processing will also be issued. Beshear mentioned that the license caps are designed to prevent market saturation, which could negatively impact both patients and businesses. The program has the flexibility to expand based on demand and the inclusion of additional qualifying conditions.

These developments in Kentucky are likely to be welcome news to the entire cannabis industry, including entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), since they mean that the rolling back of prohibition is underway in yet another U.S. state and the people there will soon have the option of using medical marijuana products to manage some of the illnesses they face for which medical cannabis is helpful.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

The 5th Annual NECANN New Jersey Cannabis Convention Projected to Witness Mammoth Turnout

The NECANN New Jersey Cannabis Convention will be held in partnership with 420NJevents at the Atlantic City Convention Center, September 6-7. As the NECANN family continues to grow every year, the turnout this year is expected to cross 4,000+ attendees with 200 exhibitors showcasing their innovative business ideas.

The NECANN New Jersey Cannabis Convention has developed robust networking and business connections since its first event in 2019. The convention will be attended by influential canna traders, license holders, dispensary owners, suppliers, investors, ancillary industries, and industry leaders from the East Coast and beyond. New Jersey has a thriving cannabis market, and the NECANN Convention is considered a powerful business platform for the region’s cannabis trading community.

Local traders, growers, and entrepreneurs, set up exhibitor booths to showcase their innovative products, and services. Industry thought leaders and experts will share insights on important trends in the cannabis industry. Attendees can discover the newest canna products and enjoy the unique experiences for which the New Jersey NECANN event is well known.

The NECANN New Jersey Convention strives to unite the local cannabis community by offering phenomenal networking and business opportunities for the region. The event will be graced by important cannabis industry leaders and investors looking for the best investment avenues. Local traders can leverage this key opportunity to learn the latest industry trends in order to stay in line with growing competition. They can also connect with serious investors to establish long-term business ties.

The NECANN event is one of the largest cannabis events in the northeast. The event offers collaborative business opportunities and high returns for sponsors, exhibitors, traders, and regional cannabis businesses. Exhibitor spaces and sponsorships are available for interested parties.

To know more, please visit https://cnw.fm/VbYEO

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN